Biomay, a biotech contract development and manufacturing organization based in Vienna, Austria, is proud to announce the successful completion of an FDA inspection, qualifying Biomay as a cGMP manufacturer and supplier of recombinant nuclease Cas9 for use in gene editing therapies. The FDA inspection is a significant milestone for Biomay, as it solidifies the organization’s commitment to quality…
No responses yet